<DOC>
	<DOCNO>NCT01413893</DOCNO>
	<brief_summary>An extension study linifanib subject advance metastatic solid tumor .</brief_summary>
	<brief_title>An Extension Study Linifanib ( ABT-869 ) Subjects With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>This study design evaluate safety linifanib subject advance metastatic solid tumor .</detailed_description>
	<criteria>Inclusion Criteria 1 . Subject complete previous study utilize linifanib ( per criterion previous study ) active assign linifanib study complete investigator believe continued treatment linifanib best interest subject . 2 . Women childbearing potential men must agree use adequate contraception ( one follow list ) prior study entry , duration study participation 90 day follow completion therapy . Women childbearing potential must negative urine pregnancy test within 7 day prior initiation treatment and/or post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential : total abstinence sexual intercourse ( minimum one complete menstrual cycle ) ; vasectomize partner ( ) ; Hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration ; subject currently use hormonal contraceptive , also use barrier method study 1 month study completion ; intrauterine device ( IUD ) ; doublebarrier method ( condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) ; Additionally , male subject ( include vasectomize ) whose partner pregnant might pregnant must agree use condom duration study 90 day follow completion therapy . 3 . Is capable understand comply parameter outline protocol able sign inform consent , approve Independent Ethic Committee ( IEC ) /Institutional Review Board ( IRB ) prior initiation screen studyspecific procedure . Exclusion Criteria 1 . Subject discontinue linifanib administration complete prior study ( due disease progression , toxicity , withdrawal consent , ) . 2 . Subject medical condition opinion investigator place subject unacceptably high risk toxicity . 3 . Subject lactate pregnant female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>